Switch theme
Sign up to access all valuation multiples
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
2006
129
LTM Revenue $96.8M
LTM EBITDA $12.6M
$240M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
OptimizeRx has a last 12-month revenue (LTM) of $96.8M and a last 12-month EBITDA of $12.6M.
In the most recent fiscal year, OptimizeRx achieved revenue of $92.1M and an EBITDA of -$8.9M.
OptimizeRx expects next 12-month revenue of XXX and NTM EBITDA of XXX
See OptimizeRx valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $96.8M | XXX | $92.1M | XXX | XXX | XXX |
| Gross Profit | $61.4M | XXX | $59.4M | XXX | XXX | XXX |
| Gross Margin | 63% | XXX | 64% | XXX | XXX | XXX |
| EBITDA | $12.6M | XXX | -$8.9M | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | -10% | XXX | XXX | XXX |
| EBIT | -$5.9M | XXX | -$6.2M | XXX | XXX | XXX |
| EBIT Margin | -6% | XXX | -7% | XXX | XXX | XXX |
| Net Profit | $7.9M | XXX | -$20.1M | XXX | XXX | XXX |
| Net Margin | 8% | XXX | -22% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $19.4M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, OptimizeRx's stock price is $12.
OptimizeRx has current market cap of $224M, and EV of $240M.
See OptimizeRx trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $240M | $224M | XXX | XXX | XXX | XXX | $0.42 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, OptimizeRx has market cap of $224M and EV of $240M.
OptimizeRx's trades at 2.6x EV/Revenue multiple, and -27.0x EV/EBITDA.
Equity research analysts estimate OptimizeRx's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
OptimizeRx has a P/E ratio of 28.4x.
See valuation multiples for OptimizeRx and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $224M | XXX | $224M | XXX | XXX | XXX |
| EV (current) | $240M | XXX | $240M | XXX | XXX | XXX |
| EV/Revenue | 2.5x | XXX | 2.6x | XXX | XXX | XXX |
| EV/EBITDA | 19.1x | XXX | -27.0x | XXX | XXX | XXX |
| EV/EBIT | -40.7x | XXX | -38.7x | XXX | XXX | XXX |
| EV/Gross Profit | 3.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 28.4x | XXX | -11.1x | XXX | XXX | XXX |
| EV/FCF | 40.8x | XXX | 54.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialOptimizeRx's last 12 month revenue growth is 12%
OptimizeRx's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.5M for the same period.
OptimizeRx's rule of 40 is -18% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
OptimizeRx's rule of X is 42% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for OptimizeRx and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 12% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 13% | XXX | -10% | XXX | XXX | XXX |
| EBITDA Growth | 20% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -18% | XXX | 2% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 42% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.7M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 71% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Alcidion Group | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Doctor Care Anywhere | XXX | XXX | XXX | XXX | XXX | XXX |
| Echo IQ | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
OptimizeRx acquired XXX companies to date.
Last acquisition by OptimizeRx was XXXXXXXX, XXXXX XXXXX XXXXXX . OptimizeRx acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was OptimizeRx founded? | OptimizeRx was founded in 2006. |
| Where is OptimizeRx headquartered? | OptimizeRx is headquartered in United States of America. |
| How many employees does OptimizeRx have? | As of today, OptimizeRx has 129 employees. |
| Who is the CEO of OptimizeRx? | OptimizeRx's CEO is Mr. Stephen L. Silvestro. |
| Is OptimizeRx publicy listed? | Yes, OptimizeRx is a public company listed on NAS. |
| What is the stock symbol of OptimizeRx? | OptimizeRx trades under OPRX ticker. |
| When did OptimizeRx go public? | OptimizeRx went public in 2009. |
| Who are competitors of OptimizeRx? | Similar companies to OptimizeRx include e.g. Benevolent AI, Alcidion Group, CurveBeam AI, Doctor Care Anywhere. |
| What is the current market cap of OptimizeRx? | OptimizeRx's current market cap is $224M |
| What is the current revenue of OptimizeRx? | OptimizeRx's last 12 months revenue is $96.8M. |
| What is the current revenue growth of OptimizeRx? | OptimizeRx revenue growth (NTM/LTM) is 12%. |
| What is the current EV/Revenue multiple of OptimizeRx? | Current revenue multiple of OptimizeRx is 2.5x. |
| Is OptimizeRx profitable? | Yes, OptimizeRx is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of OptimizeRx? | OptimizeRx's last 12 months EBITDA is $12.6M. |
| What is OptimizeRx's EBITDA margin? | OptimizeRx's last 12 months EBITDA margin is 13%. |
| What is the current EV/EBITDA multiple of OptimizeRx? | Current EBITDA multiple of OptimizeRx is 19.1x. |
| What is the current FCF of OptimizeRx? | OptimizeRx's last 12 months FCF is $5.9M. |
| What is OptimizeRx's FCF margin? | OptimizeRx's last 12 months FCF margin is 6%. |
| What is the current EV/FCF multiple of OptimizeRx? | Current FCF multiple of OptimizeRx is 40.8x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
